Quarterly ResultAug 5, 2026, 04:19 PM
Akebia Q2 Net Loss $8.9M; Vafseo Revenue Up 34% to $21.3M
AI Summary
Akebia Therapeutics reported Q2 2026 financial results, with Vafseo net product revenues growing 34% sequentially to $21.3 million. However, total revenues decreased to $49.1 million, primarily due to lower Auryxia sales, resulting in a net loss of $8.9 million. The company also announced positive interim results from the VOICE trial for Vafseo, the initiation of a Phase 2 trial for ebribafusp, and strengthened its Vafseo intellectual property portfolio.
Key Highlights
- Vafseo net product revenues grew to $21.3 million in Q2 2026, a 34% increase over Q1.
- Total revenues were $49.1 million in Q2 2026, down from $62.5 million in Q2 2025.
- Auryxia net product revenues were $25.5 million in Q2 2026, compared to $47.2 million in Q2 2025.
- Net loss was $8.9 million in Q2 2026, compared to net income of $0.2 million in Q2 2025.
- Cash and cash equivalents were $155.5 million as of June 30, 2026.
- VOICE trial interim analysis showed improved safety outcomes for Vafseo vs. ESA (p=0.0016).
- Initiated Phase 2 open-label basket trial for ebribafusp, with initial data expected in 2027.
- Strengthened Vafseo IP with new Orange Book-listed patent (expiring June 2034).
Price Impact
More from AKBA